An Experimental Group A Streptococcus Vaccine That Reduces Pharyngitis and Tonsillitis in a Nonhuman Primate Model
Tania Rivera-Hernandez, Diane G Carnathan, Scott Jones, Amanda J Cork, Mark R Davies, Peter M Moyle, Istvan Toth, Michael R Batzloff, James McCarthy, Victor Nizet, David Goldblatt, Guido Silvestri, Mark J Walker
mBio | AMER SOC MICROBIOLOGY | Published : 2019
Group A Streptococcus (GAS) infections account for an estimated 500,000 deaths every year. This bacterial pathogen is responsible for a variety of mild and life-threatening infections and the triggering of chronic autoimmune sequelae. Pharyngitis caused by group A Streptococcus (GAS), but not asymptomatic GAS carriage, is a prerequisite for acute rheumatic fever (ARF). Repeated bouts of ARF may trigger rheumatic heart disease (RHD), a major cause of heart failure and stroke accounting for 275,000 deaths annually. A vaccine that prevents pharyngitis would markedly reduce morbidity and mortality from ARF and RHD. Nonhuman primates (NHPs) have been utilized to model GAS diseases, and experiment..View full abstract
Awarded by OFFICE OF THE DIRECTOR, NATIONAL INSTITUTES OF HEALTH
This work was supported by the National Health and Medical Research Council of Australia, the U.S. National Institutes of Health, the Queensland-Emory Development Initiative, and the Coalition to Advance Vaccines Against Group A Streptococcus.